PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15039452-2 2004 We previously found that the biguanide metformin, an antidiabetic agent, causes a significant increase of plasma active GLP-1 level in the presence of dipeptidyl peptidase IV (DPPIV) inhibitor in normal rats. Metformin 39-48 dipeptidylpeptidase 4 Rattus norvegicus 151-174 15039452-2 2004 We previously found that the biguanide metformin, an antidiabetic agent, causes a significant increase of plasma active GLP-1 level in the presence of dipeptidyl peptidase IV (DPPIV) inhibitor in normal rats. Metformin 39-48 dipeptidylpeptidase 4 Rattus norvegicus 176-181 12419322-2 2002 There are two possible mechanisms for this effect: (1) metformin inhibits dipeptidyl peptidase IV (DPPIV), an enzyme degrading GLP-1, and (2) metformin enhances GLP-1 secretion. Metformin 55-64 dipeptidylpeptidase 4 Rattus norvegicus 74-97 12419322-2 2002 There are two possible mechanisms for this effect: (1) metformin inhibits dipeptidyl peptidase IV (DPPIV), an enzyme degrading GLP-1, and (2) metformin enhances GLP-1 secretion. Metformin 55-64 dipeptidylpeptidase 4 Rattus norvegicus 99-104 12419322-5 2002 Metformin treatment (30, 100, and 300mg/kg) increased plasma active GLP-1 levels dose-dependently in DPPIV-deficient F344/DuCrj rats (approximately 1.6-fold at 3 and 5h after administration of 300mg/kg). Metformin 0-9 dipeptidylpeptidase 4 Rattus norvegicus 101-106 12419322-8 2002 In DPPIV-positive F344/Jcl rats, coadministration of metformin (300mg/kg) and valine-pyrrolidide (30mg/kg) resulted in elevation of plasma active GLP-1, but neither metformin nor valine-pyrrolidide treatment alone had any effect. Metformin 53-62 dipeptidylpeptidase 4 Rattus norvegicus 3-8 15464987-0 2004 Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Metformin 44-53 dipeptidylpeptidase 4 Rattus norvegicus 14-37 15464987-6 2004 Metformin and pioglitazone significantly (P<0.05) reduced serum DPP-IV activity and glycosylated hemoglobin. Metformin 0-9 dipeptidylpeptidase 4 Rattus norvegicus 67-73 15464987-10 2004 We propose the in vivo inhibitory effects observed with metformin and pioglitazone on serum DPP-IV activity results from reduced DPP-IV secretion. Metformin 56-65 dipeptidylpeptidase 4 Rattus norvegicus 92-98 15464987-10 2004 We propose the in vivo inhibitory effects observed with metformin and pioglitazone on serum DPP-IV activity results from reduced DPP-IV secretion. Metformin 56-65 dipeptidylpeptidase 4 Rattus norvegicus 129-135 15039452-11 2004 These results demonstrate that the combination therapy of metformin with DPPIV inhibitor leads to reduced food intake and body weight gain, most likely through the significant increase of plasma GLP-1 level. Metformin 58-67 dipeptidylpeptidase 4 Rattus norvegicus 73-78 21345512-1 2011 AIM: The combination of metformin and a dipeptidyl peptidase 4 (DPP-4) inhibitor has been shown to be an effective, safe, and well-tolerated treatment for type 2 diabetes. Metformin 24-33 dipeptidylpeptidase 4 Rattus norvegicus 64-69